NEW YORK (360Dx) – Luminex this week said that it recently began clinical studies for a gastrointestinal assay on the Verigene II, its sample-to-answer benchtop molecular diagnostic system in development. The Verigene II system contains the same core nanoparticle chemistry as the firm's current Verigene system. It consolidates four individual consumables into a single cartridge within a closed system for a simpler workflow, the firm said. At any time, the Verigene II fully automated system will support up to six modules for random access testing.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.